Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Treasury Shares (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Treasury Shares for 16 consecutive years, with $953713.0 as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 14.0% to $953713.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $953713.0, a 14.0% increase, with the full-year FY2025 number at $953713.0, up 14.0% from a year prior.
  • Treasury Shares was $953713.0 for Q4 2025 at Anika Therapeutics, up from $279754.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $953713.0 in Q4 2025 to a low of $29000.0 in Q3 2023.
  • A 5-year average of $395971.3 and a median of $214500.0 in 2023 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: crashed 77.93% in 2023, then surged 427.84% in 2025.
  • Anika Therapeutics' Treasury Shares stood at $158297.0 in 2021, then skyrocketed by 326.67% to $675405.0 in 2022, then plummeted by 72.16% to $188000.0 in 2023, then soared by 344.98% to $836562.0 in 2024, then grew by 14.0% to $953713.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Treasury Shares are $953713.0 (Q4 2025), $279754.0 (Q2 2025), and $241000.0 (Q1 2025).